...
首页> 外文期刊>Cancer Cell >A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
【24h】

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

机译:泛素特异性蛋白酶7的小分子抑制剂诱导多发性骨髓瘤细胞凋亡并克服硼替佐米耐药性。

获取原文
获取原文并翻译 | 示例
           

摘要

Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility. Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies. Biochemical and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity. In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival. Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity. Our preclinical study therefore supports clinical evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.
机译:硼替佐米疗法已被证明可成功治疗复发/难治,复发和新诊断的多发性骨髓瘤(MM)。但是,剂量限制的毒性和耐药性的发展限制了其长期使用。在这里,我们显示P5091是去泛素化酶USP7的抑制剂,USP7可以诱导对常规和硼替佐米疗法产生耐药性的MM细胞凋亡。生化和遗传研究表明,HDM2和p21的阻滞消除了P5091诱导的细胞毒性。在动物肿瘤模型研究中,P5091具有良好的耐受性,可抑制肿瘤生长并延长生存期。将P5091与来那度胺,HDAC抑制剂SAHA或地塞米松组合可触发协同的抗MM活性。因此,我们的临床前研究支持USP7抑制剂(单独或联合使用)作为潜在的MM治疗的临床评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号